Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Prepaid Assets (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Prepaid Assets for 13 consecutive years, with $6.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets fell 12.08% to $6.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.8 million, a 12.08% decrease, with the full-year FY2024 number at $4.3 million, changed N/A from a year prior.
  • Prepaid Assets was $6.8 million for Q3 2025 at Theravance Biopharma, up from $5.6 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $12.4 million in Q2 2021 to a low of $4.1 million in Q1 2025.
  • A 5-year average of $7.4 million and a median of $7.6 million in 2024 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: skyrocketed 82.79% in 2021, then plummeted 54.75% in 2022.
  • Theravance Biopharma's Prepaid Assets stood at $9.9 million in 2021, then fell by 22.74% to $7.7 million in 2022, then increased by 17.1% to $9.0 million in 2023, then crashed by 52.46% to $4.3 million in 2024, then skyrocketed by 57.82% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Prepaid Assets are $6.8 million (Q3 2025), $5.6 million (Q2 2025), and $4.1 million (Q1 2025).